BIO-TECHNE Corp Pre-Tax Income
BIO-TECHNE Corp (TECH) reported Pre-Tax Income of $240.68 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-24
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $70.68M.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $71.22M, a 86.09% increase year-over-year.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $50.78M, a 18.44% increase year-over-year.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $47.99M, a 19.47% increase year-over-year.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2026 was $240.68M, a 144.44% increase from fiscal 2025.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $98.46M, a 46.97% decline from fiscal 2024.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $185.69M, a 45.17% decline from fiscal 2023.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $338.66M, a 12.37% increase from fiscal 2022.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $70.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $141.91M derived: sum of 2 quarters · filed 2026-08-24 | $192.69M derived: sum of 3 quarters · filed 2026-08-24 | $240.68M 10-K · filed 2026-08-24 | |||
| 2026-03-31 | $71.22M 10-Q · filed 2026-05-06 | $122.01M derived: sum of 2 quarters · filed 2026-05-06 | $170.00M 10-Q · filed 2026-05-06 | $147.14M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-12-31 | $50.78M 10-Q · filed 2026-02-04 | $98.78M 10-Q · filed 2026-02-04 | $75.92M derived: sum of 3 quarters · filed 2026-08-24 | $114.19M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-09-30 | $47.99M 10-Q · filed 2025-11-05 | $25.13M derived: sum of 2 quarters · filed 2026-08-24 | $63.41M derived: sum of 3 quarters · filed 2026-08-24 | $106.28M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2025-06-30 | -$22.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $15.41M derived: sum of 2 quarters · filed 2026-08-24 | $58.29M derived: sum of 3 quarters · filed 2026-08-24 | $98.46M 10-K · filed 2026-08-24 | |||
| 2025-03-31 | $38.27M 10-Q · filed 2026-05-06 | $81.15M derived: sum of 2 quarters · filed 2026-05-06 | $121.32M 10-Q · filed 2026-05-06 | $162.98M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-12-31 | $42.88M 10-Q · filed 2026-02-04 | $83.05M 10-Q · filed 2026-02-04 | $124.71M derived: sum of 3 quarters · filed 2026-08-24 | $185.79M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-09-30 | $40.17M 10-Q · filed 2025-11-05 | $81.83M derived: sum of 2 quarters · filed 2026-08-24 | $142.92M derived: sum of 3 quarters · filed 2026-08-24 | $176.30M derived: sum of 4 quarters · filed 2026-08-24 | |||
| 2024-06-30 | $41.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $102.75M derived: sum of 2 quarters · filed 2026-08-24 | $136.13M derived: sum of 3 quarters · filed 2026-08-24 | $185.69M 10-K · filed 2026-08-24 | |||
| 2024-03-31 | $61.08M 10-Q · filed 2025-05-08 | $94.47M derived: sum of 2 quarters · filed 2025-05-08 | $144.03M 10-Q · filed 2025-05-08 | $232.34M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-12-31 | $33.39M 10-Q · filed 2025-02-06 | $82.94M 10-Q · filed 2025-02-06 | $171.26M derived: sum of 3 quarters · filed 2025-08-22 | $251.46M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-09-30 | $49.56M 10-Q · filed 2024-11-05 | $137.87M derived: sum of 2 quarters · filed 2025-08-22 | $218.07M derived: sum of 3 quarters · filed 2025-08-22 | $284.50M derived: sum of 4 quarters · filed 2025-08-22 | |||
| 2023-06-30 | $88.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $168.51M derived: sum of 2 quarters · filed 2025-08-22 | $234.94M derived: sum of 3 quarters · filed 2025-08-22 | $338.66M 10-K · filed 2025-08-22 | |||
| 2023-03-31 | $80.20M 10-Q · filed 2024-05-06 | $146.63M derived: sum of 2 quarters · filed 2024-05-06 | $250.34M 10-Q · filed 2024-05-06 | $329.39M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-12-31 | $66.43M 10-Q · filed 2024-02-07 | $170.15M 10-Q · filed 2024-02-07 | $249.20M derived: sum of 3 quarters · filed 2024-08-22 | $317.97M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-09-30 | $103.72M 10-Q · filed 2023-11-07 | $182.77M derived: sum of 2 quarters · filed 2024-08-22 | $251.54M derived: sum of 3 quarters · filed 2024-08-22 | $337.72M derived: sum of 4 quarters · filed 2024-08-22 | |||
| 2022-06-30 | $79.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $147.82M derived: sum of 2 quarters · filed 2024-08-22 | $234.00M derived: sum of 3 quarters · filed 2024-08-22 | $301.39M 10-K · filed 2024-08-22 | |||
| 2022-03-31 | $68.77M 10-Q · filed 2023-05-08 | $154.95M derived: sum of 2 quarters · filed 2023-05-08 | $222.33M 10-Q · filed 2023-05-08 | $229.45M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-12-31 | $86.18M 10-Q · filed 2023-02-07 | $153.56M 10-Q · filed 2023-02-07 | $160.68M derived: sum of 3 quarters · filed 2023-08-23 | $206.03M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-09-30 | $67.38M 10-Q · filed 2022-11-07 | $74.50M derived: sum of 2 quarters · filed 2023-08-23 | $119.85M derived: sum of 3 quarters · filed 2023-08-23 | $176.22M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-06-30 | $7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $52.47M derived: sum of 2 quarters · filed 2023-08-23 | $108.83M derived: sum of 3 quarters · filed 2023-08-23 | $148.18M 10-K · filed 2023-08-23 | |||
| 2021-03-31 | $45.35M 10-Q · filed 2022-05-09 | $101.72M derived: sum of 2 quarters · filed 2022-05-09 | $141.06M 10-Q · filed 2022-05-09 | $202.59M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-12-31 | $56.37M 10-Q · filed 2022-02-07 | $95.71M 10-Q · filed 2022-02-07 | $157.23M derived: sum of 3 quarters · filed 2022-08-24 | $204.05M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-09-30 | $39.34M 10-Q · filed 2021-11-08 | $100.86M derived: sum of 2 quarters · filed 2022-08-24 | $147.69M derived: sum of 3 quarters · filed 2022-08-24 | $298.01M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-06-30 | $61.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $108.35M derived: sum of 2 quarters · filed 2022-08-24 | $258.67M derived: sum of 3 quarters · filed 2022-08-24 | $276.48M 10-K · filed 2022-08-24 | |||
| 2020-03-31 | $46.82M 10-Q · filed 2021-05-07 | $197.15M derived: sum of 2 quarters · filed 2021-05-07 | $214.95M 10-Q · filed 2021-05-07 | $237.74M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-12-31 | $150.33M 10-Q · filed 2021-02-08 | $168.13M 10-Q · filed 2021-02-08 | $190.92M derived: sum of 3 quarters · filed 2021-08-25 | $240.79M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-09-30 | $17.81M 10-Q · filed 2020-11-09 | $40.59M derived: sum of 2 quarters · filed 2021-08-25 | $90.47M derived: sum of 3 quarters · filed 2021-08-25 | $112.24M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-06-30 | $22.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $72.66M derived: sum of 2 quarters · filed 2021-08-25 | $94.43M derived: sum of 3 quarters · filed 2021-08-25 | $112.02M 10-K · filed 2021-08-25 | |||
| 2019-03-31 | $49.88M 10-Q · filed 2020-05-11 | $71.64M derived: sum of 2 quarters · filed 2020-05-11 | $89.23M 10-Q · filed 2020-05-11 | $145.50M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-12-31 | $21.77M 10-Q · filed 2020-02-06 | $39.35M 10-Q · filed 2020-02-06 | $95.62M derived: sum of 3 quarters · filed 2020-08-26 | $120.61M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-09-30 | $17.59M 10-Q · filed 2019-11-06 | $73.86M derived: sum of 2 quarters · filed 2020-08-26 | $98.84M derived: sum of 3 quarters · filed 2020-08-26 | $120.57M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-06-30 | $56.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | $81.25M derived: sum of 2 quarters · filed 2020-08-26 | $102.98M derived: sum of 3 quarters · filed 2020-08-26 | $125.95M 10-K · filed 2020-08-26 | |||
| 2018-03-31 | $24.98M 10-Q · filed 2019-05-07 | $46.71M derived: sum of 2 quarters · filed 2019-05-07 | $69.68M 10-Q · filed 2019-05-07 | $107.53M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-12-31 | $21.73M 10-Q · filed 2019-02-07 | $44.70M 10-Q · filed 2019-02-07 | $82.55M derived: sum of 3 quarters · filed 2019-11-06 | $113.69M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-09-30 | $22.97M 10-Q · filed 2018-11-07 | $60.81M derived: sum of 2 quarters · filed 2019-11-06 | $91.96M derived: sum of 3 quarters · filed 2019-11-06 | $107.14M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-06-30 | $37.85M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06 | $68.99M derived: sum of 2 quarters · filed 2019-11-06 | $84.18M derived: sum of 3 quarters · filed 2019-11-06 | $111.96M 10-K/A · filed 2019-11-06 | |||
| 2017-03-31 | $31.14M 10-Q · filed 2018-05-09 | $30.03M 10-Q · filed 2017-05-10 | $46.33M derived: sum of 2 quarters · filed 2018-05-09 | $74.11M 10-Q · filed 2018-05-09 | $67.70M 10-Q · filed 2017-05-10 | $111.88M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-12-31 | $15.19M 10-Q · filed 2018-02-08 | $13.54M 10-Q · filed 2017-02-09 | $42.97M 10-Q · filed 2018-02-08 | $37.67M 10-Q · filed 2017-02-09 | $80.74M derived: sum of 3 quarters · filed 2018-08-27 | $123.23M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-09-30 | $27.79M 10-Q · filed 2017-11-09 | $24.13M 10-Q · filed 2016-11-09 | $65.56M derived: sum of 2 quarters · filed 2018-08-27 | $108.05M derived: sum of 3 quarters · filed 2018-08-27 | $143.42M derived: sum of 4 quarters · filed 2018-08-27 | ||
| 2016-06-30 | $37.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | $80.26M derived: sum of 2 quarters · filed 2018-08-27 | $115.63M derived: sum of 3 quarters · filed 2018-08-27 | $147.48M 10-K · filed 2018-08-27 | |||
| 2016-03-31 | $42.49M 10-Q · filed 2017-05-10 | $77.86M derived: sum of 2 quarters · filed 2017-05-10 | $109.71M 10-Q · filed 2017-05-10 | $147.95M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-12-31 | $35.37M 10-Q · filed 2017-02-09 | $67.22M 10-Q · filed 2017-02-09 | $105.46M derived: sum of 3 quarters · filed 2017-09-07 | $144.22M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-09-30 | $31.85M 10-Q · filed 2016-11-09 | $70.09M derived: sum of 2 quarters · filed 2017-09-07 | $108.85M derived: sum of 3 quarters · filed 2017-09-07 | $151.41M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-06-30 | $38.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $77.00M derived: sum of 2 quarters · filed 2017-09-07 | $119.56M derived: sum of 3 quarters · filed 2017-09-07 | $154.16M 10-K · filed 2017-09-07 | |||
| 2015-03-31 | $38.76M 10-Q · filed 2016-05-10 | $81.32M derived: sum of 2 quarters · filed 2016-05-10 | $115.92M 10-Q · filed 2016-05-10 | $155.37M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-12-31 | $42.56M 10-Q · filed 2016-02-09 | $77.16M 10-Q · filed 2016-02-09 | $116.61M derived: sum of 3 quarters · filed 2016-08-29 | $162.68M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-09-30 | $34.60M 10-Q · filed 2015-11-09 | $74.05M derived: sum of 2 quarters · filed 2016-08-29 | $120.12M derived: sum of 3 quarters · filed 2016-08-29 | $156.34M derived: sum of 4 quarters · filed 2016-08-29 | |||
| 2014-06-30 | $39.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $85.52M derived: sum of 2 quarters · filed 2016-08-29 | $121.74M derived: sum of 3 quarters · filed 2016-08-29 | $161.39M 10-K · filed 2016-08-29 | |||
| 2014-03-31 | $46.07M 10-Q · filed 2015-05-11 | $82.29M derived: sum of 2 quarters · filed 2015-05-11 | $121.94M 10-Q · filed 2015-05-11 | $162.71M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-12-31 | $36.22M 10-Q · filed 2015-02-09 | $75.87M 10-Q · filed 2015-02-09 | $116.64M derived: sum of 3 quarters · filed 2015-08-31 | $161.10M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-09-30 | $39.65M 10-Q · filed 2014-11-10 | $80.42M derived: sum of 2 quarters · filed 2015-08-31 | $124.88M derived: sum of 3 quarters · filed 2015-08-31 | $162.33M derived: sum of 4 quarters · filed 2015-08-31 | |||
| 2013-06-30 | $40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $85.23M derived: sum of 2 quarters · filed 2015-08-31 | $122.68M derived: sum of 3 quarters · filed 2015-08-31 | $160.66M 10-K · filed 2015-08-31 | |||
| 2013-03-31 | $44.47M 10-Q · filed 2014-05-12 | $81.91M derived: sum of 2 quarters · filed 2014-05-12 | $119.90M 10-Q · filed 2014-05-12 | $160.51M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-12-31 | $37.45M 10-Q · filed 2014-02-04 | $75.43M 10-Q · filed 2014-02-04 | $116.05M derived: sum of 3 quarters · filed 2014-08-29 | $159.25M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-09-30 | $37.99M 10-Q · filed 2013-11-12 | $78.60M derived: sum of 2 quarters · filed 2014-08-29 | $121.81M derived: sum of 3 quarters · filed 2014-08-29 | $159.68M derived: sum of 4 quarters · filed 2014-08-29 | |||
| 2012-06-30 | $40.62M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $83.82M derived: sum of 2 quarters · filed 2014-08-29 | $121.69M derived: sum of 3 quarters · filed 2014-08-29 | $162.19M 10-K · filed 2014-08-29 | |||
| 2012-03-31 | $43.20M 10-Q · filed 2013-05-10 | $81.08M derived: sum of 2 quarters · filed 2013-05-10 | $121.58M 10-Q · filed 2013-05-10 | $164.55M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-12-31 | $37.87M 10-Q · filed 2013-02-11 | $78.37M 10-Q · filed 2013-02-11 | $121.34M derived: sum of 3 quarters · filed 2013-08-29 | $166.73M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-09-30 | $40.50M 10-Q · filed 2012-11-09 | $83.47M derived: sum of 2 quarters · filed 2013-08-29 | $128.85M derived: sum of 3 quarters · filed 2013-08-29 | $166.53M derived: sum of 4 quarters · filed 2013-08-29 | |||
| 2011-06-30 | $42.97M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-29 | $88.36M derived: sum of 2 quarters · filed 2013-08-29 | $126.03M derived: sum of 3 quarters · filed 2013-08-29 | $164.98M 10-K · filed 2013-08-29 | |||
| 2011-03-31 | $45.38M 10-Q · filed 2012-05-10 | $83.06M derived: sum of 2 quarters · filed 2012-05-10 | $122.01M 10-Q · filed 2012-05-10 | ||||
| 2010-12-31 | $37.67M 10-Q · filed 2012-02-07 | $76.63M 10-Q · filed 2012-02-07 | |||||
| 2010-09-30 | $38.95M 10-Q · filed 2011-11-09 | ||||||
| 2010-06-30 | $156.45M 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |